Is the CSL share price a buy right now?
Image source: Getty Images
The CSL Ltd (ASX: CSL) share price has had a difficult time during President Trump’s term so far. In 2025 to date, the ASX biotech share has fallen by almost 30%, as the chart below shows.
The diversification of the business hasn’t seemed to have helped it in the minds of investors amid the challenging operating environment.
In FY26, it’s expecting to grow its revenue by between 4% to 5% and deliver underlying net profit (NPATA) growth of between 7% to 10%, excluding restructuring costs. The guidance also assumes no impact from US pharmaceutical sector tariffs.
This FY26 guidance wasn’t enough to excite investors and neither was the plan to split up its business.
Demerger plans
CSL says that it intends to…
